Cybin Inc. (NEO:CYBN)
Canada flag Canada · Delayed Price · Currency is CAD
10.40
-0.29 (-2.71%)
Jul 29, 2025, 3:59 PM EDT

Cybin Company Description

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

The company is headquartered in Toronto, Canada.

Cybin Inc.
Cybin logo
CountryCanada
IndustryBiotechnology
SectorHealthcare
Employees50
CEODouglas Drysdale

Contact Details

Address:
100 King Street West
Toronto, Ontario M5X 1C9
Canada
Websitecybin.com

Stock Details

Ticker SymbolCYBN
ExchangeCboe Canada
Fiscal YearApril - March
Reporting CurrencyCAD
ISIN NumberCA23256X1006
SIC Code2834

Key Executives

NamePosition
Douglas L. DrysdaleChief Executive Officer
Eric So L.L.B.Co-Founder, President and Executive Chairman
Paul GlavineCo-Founder, Chief Growth Officer and Director
Greg CaversChief Financial Officer
Aaron BartloneChief Operating Officer
George TzirasChief Business Officer and Director
John KanakisCo-Founder
Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer
Lori ChallengerChief Compliance, Ethics and Administrative Officer
Gabriel FahelChief Legal Officer and Corporate Secretary